SAN DIEGO, CA--(Marketwired - Jul 31, 2013) - Medistem, Inc. (PINKSHEETS: MEDS), announced today it's President and Chief Scientific Officer, Thomas E. Ichim, Ph.D., presented at the CRYO 2013 Conference held in Bethesda, Maryland on Monday July 29th.
The CRYO 2013 Conference was sponsored by the Society for Cryobiology, which, this year, is celebrating 50 years of member accomplishments.The Society for Cryobiology, founded in1964, attracts experts from biological, medical and physical sciences and its mission is to promote scientific research in low temperature biology, to improve scientific understanding in this field, and to disseminate and apply this knowledge to the benefit of mankind.
Dr. Ichim presented the Company's cryopreservation process in the manufacturing and shipment of its ERC-124 product, an allogeneic universal donor stem cell derived from the endometrium (lining of the uterus).
"Through the use of cryopreservation we have been able to ship our ERC-124 product internationally with no loss of therapeutic potency.This has allowed us to centralize our ERC-124 manufacturing process and ship to point of care sites worldwide," said Dr. Ichim."We are honored to have been selected by the Society for Cryobiology to present details of our processes at its 50th Annual Meeting."
Medistem is the only company that collects stem cells from the menstrual blood of healthy volunteers, expands the stem cells so that one donor generates 20,000 patient doses, and has the ability to effectively deliver these stem cells internationally.Once delivered to the point of care, Medistem's ERC-124 product can be stored frozen for up to one year, and can be utilized after a simple thawing process.
Medistem has received FDA clearance to begin a clinical study using its ERC-124 product in the United States to treat critical limb ischemia.The Company anticipates initiating this clinical study in the fourth quarter of this year.In addition, the Company is also conducting a 60 patient double blind, placebo controlled clinical trial in Moscow, Russia, at the Backulev Center, to treat congestive heart failure patients using its ERC-124 product.Further information about the congestive heart failure trial can be found at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599750/pdf/1479-5876-11-56.pdf.
About Medistem, Inc.
Medistem, Inc., is focused on the development of the Endometrial Regenerative Cell (ERC), a universal donor adult stem cell product. ERCs possess specialized abilities to stimulate new blood vessel growth and can differentiate into lung, liver, heart, brain, bone, cartilage, fat and pancreatic tissue. These unique properties have applications for treatment of critical limb ischemia (CLI), congestive heart failure (CHF), neurodegenerative diseases, liver failure, kidney failure, and diabetes. ERCs have been cleared by the FDA to begin studies in the United States.In January 2012, we announced the initiation of our RECOVER-ERC (Non-Revascularizable IschEmic Cardiomyopathy treated with Retrograde COronary Sinus Venous DElivery of Cell TheRapy) Phase II clinical trial.This trial is being conducted at the Bakulev Scientific Center for Cardiovascular Surgery, Moscow, Russia.The trial is a 60 patient double blind placebo controlled study evaluating safety and efficacy of ERCs in end stage CHF patients.
Certain statements herein may be forward-looking and involve risks and uncertainties.Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Medistem, Inc.These can be identified by the use of forwardlooking words, such as "believes", "expects", "may", "intends", "anticipates", "plans", "estimates", or any other analogous or similar expressions intended to identify forwardlooking statements. These forwardlooking statements and estimates as to future performance, estimates, and other statements contained herein regarding matters that are not historical facts, are only predictions and actual events or results may differ materially. We cannot assure or guarantee that any future results described in this presentation will be achieved, and actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Go here to read the rest:
Medistem Presents Its ERC-124 Stem Cell Product at CRYO 2013